Pricing watchdog judges Wegovy too pricey in the USA

21 October 2022
icer_big

Boston, Massachusetts-based non-profit The Institute for Clinical and Economic Review (ICER) has issued its  final report into the cost-effectiveness of the latest generation of weight loss treatments.

The group has been comparing the comparative clinical effectiveness and value of Novo Nordisk’s (NOVO: N) Wegovy (semaglutide) and Saxenda (liraglutide), as well as Qsymia (phentermine/topiramate), from Vivus Pharmaceuticals (Nasdaq: VVUS), and Contrave (bupropion/naltrexone), from Currax Pharma.

Wegovy in particular has attracted a lot of interest and excitement, with evidence showing a dramatic impact on weight loss.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical